<DOC>
	<DOCNO>NCT00660985</DOCNO>
	<brief_summary>Phase 4 commitment pharmacokinetic study determine systemic exposure adapalene .</brief_summary>
	<brief_title>Pharmacokinetic Study Compare Systemic Exposure Differin® Gel , 0.3 % Differin® Gel , 0.1 %</brief_title>
	<detailed_description>Multi-center , double-blind , randomize , parallel group study enrol male female subject acne vulgaris . Screening take place within 14 day prior Baseline . At Baseline visit , study day Day 30 , train nurse technician apply 2 gram study medication ( either Differin® Gel , 0.3 % Differin® Gel , 0.1 % ) face , upper part chest , upper part back subject . To ensure maximal usage condition , 2 gram study medication apply daily total body surface area approximately 1000 cm² , equivalent 2 mg/cm2 . Subjects arrive clinic night visit day ( Day 1 , Day 15 Day 30 ) PK blood sample draw . Subjects discharge clinic Day 2 Day 16 follow 24-hour post-dose blood sample , Day 31 36-hour post-dose blood sample . Cutaneous safety ( local tolerability assessment ) assess , record erythema , scaling , dryness , stinging/burning sensation separate score face , upper part chest , upper part back use 4-point scale ( 0 = None 3 = Severe ) . Local tolerability assessment perform weekly Day 1 , 8 , 15 , 22 Day 30 , prior application study medication . Efficacy evaluate Inflammatory Non-inflammatory lesion count face perform Screening , Baseline ( Day 1 ) , Day 30 . Subjects routine laboratory test ( fast hematology , blood chemistry ) perform Screening Day 30 visit . Blood sample determination adapalene plasma concentration draw Day 1 , Day 15 , Day 30 morning study medication application ( pre-dose ) 1 , 2 , 4 , 6 , 8 , 10 , 12 , 16 24 hour application study medication ; additionally last study medication application ( Day 31 , 32 , 33 ) 32 , 36 , 48 72 hour post-dose . The adapalene plasma concentration determine high performance liquid chromatography ( HPLC ) fluorescence detection method .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<criteria>Male female 18 35 year age Clinical diagnosis acne vulgaris Minimum 20 Inflammatory Minimum 20 Noninflammatory lesion The subject body weight 45 100 kg , Body Mass Index ( BMI ) 18 30Kg/m2 More 1 nodule cyst face ( exclude nose ) Acne conglobata , acne fulminans , secondary acne severe acne Underlying disease dermatological condition require use interfering topical systemic therapy Pregnant nursing planning pregnancy Surgical medical condition might interfere absorption , distribution , metabolism , excretion drug Known allergies ingredient study medication History alcohol drug abuse positive test result drug abuse Positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus antibody ( HIV Ab ) Use prohibit medication prior study unless appropriate washout period document</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Acne vulgaris</keyword>
	<keyword>Differin</keyword>
	<keyword>Adapalene</keyword>
</DOC>